CLEC10A, His, Mouse
CLEC10A, His, Mouse

The purity of CLEC10A, His, Mouse is greater than 95% as determined by SEC-HPLC.

CLEC10A, His, Mouse

CLEC10A, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

CLEC10A, His, Mouse

CLEC10A, (C-type lectin domain family 10, member A), as the member of C-type lectin receptors (CLRs), plays a vital role in modulating innate immunity and adaptive immunity and has shown great potential as an immunotherapy target for cancers. However, there is no functional research of CLEC10A in prognostic risk, immunotherapy or any other treatment of lung adenocarcinoma (LUAD).
Z06062
¥63,425.00

Ask us a question
Product Introduction
Species Mouse
Protein Construction
CLEC10A (Gln57-Ser304)_x000D_
Accession # P49300		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 29.4 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 38-45 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • CLEC10A, His, Mouse
    • CLEC10A, His, Mouse

    The purity of CLEC10A, His, Mouse is greater than 95% as determined by SEC-HPLC.

  • CLEC10A, His, Mouse
    • CLEC10A, His, Mouse

    CLEC10A, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background CLEC10A, (C-type lectin domain family 10, member A), as the member of C-type lectin receptors (CLRs), plays a vital role in modulating innate immunity and adaptive immunity and has shown great potential as an immunotherapy target for cancers. However, there is no functional research of CLEC10A in prognostic risk, immunotherapy or any other treatment of lung adenocarcinoma (LUAD).
Synonyms CD301; CLEC10A; CLECSF13; CLECSF14; HML; HML2; MGL

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.